Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy

Next Previous
Trial Profile

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Oct 2025 According to an Eleva media release, The MAD study will include three dose cohorts and will be conducted in patients diagnosed with C3G to further assess the safety profile of CPV-104 in the targeted population.18 patients with C3G will receive now CPV-104 in a Multiple Ascending Dose regimen administered over a four-week period.
  • 21 Oct 2025 According to an Eleva media release, company announced ,The Safety Review Committee endorsed the study with no safety concerns identified across all four dose cohorts.
  • 21 Oct 2025 According to an Eleva media release, company announced that CPV-104, a recombinant human complement Factor H, has advanced into evaluation in patients with C3 glomerulopathy (C3G),This follows the successful completion of the single ascending dose (SAD) part of its First in Human clinical trial investigating CPV-104 in 21 healthy volunteers.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top